<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122963</url>
  </required_header>
  <id_info>
    <org_study_id>2406</org_study_id>
    <nct_id>NCT04122963</nct_id>
  </id_info>
  <brief_title>CLOSE-guided Pulmonary Vein Isolation Using High Power and Stable RF Applications</brief_title>
  <acronym>POWERAF</acronym>
  <official_title>CLOSE-guided Pulmonary Vein Isolation Using High Power and Stable RF Applications: a Randomized Study. The POWERAF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomised, controlled, unblinded,monocentric study, we aim to evaluate&#xD;
      the safety and efficacy of higher power CLOSE-guided PVI in patients referred for a first&#xD;
      ablation for paroxysmal AF. We aim to include 100 patients into two groups (1:1). The&#xD;
      experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3&#xD;
      mm for 3 seconds) compared to the control group which will receive AF ablation according to&#xD;
      the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: In a population of paroxysmal AF 'CLOSE'-guided PVI (Target Ablation index (AI)&#xD;
      &gt;550 and &gt;400 for anterior and posterior wall respectively, interlesion distance ≤6mm) has&#xD;
      been shown to obtain single-procedure durable PV isolation. However, the optimal RF power and&#xD;
      stability criteria is unknown.&#xD;
&#xD;
      OBJECTIVES: With this study, we aim at evaluation the efficacy and the safety of higher power&#xD;
      (45 watts) and stricter stability criteria (3 mm for 3 sec) as compared to a standard CLOSE&#xD;
      protocol (35 watts with stability of 3 mm for 8 sec) in patients referred for a first&#xD;
      ablation for paroxysmal AF.&#xD;
&#xD;
      POPULATION: Eligible patients are patients with paroxysmal AF who are planned for a&#xD;
      'CLOSE'-guided PV isolation for paroxysmal AF. At the time of the procedrual planning, we&#xD;
      will ask the patient his/her consent for collectio of data. We aim at including 100 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Acute procedural success</measure>
    <time_frame>At time of ablation</time_frame>
    <description>First pass pulmonary vein isolation confirmed after adenosine injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Absence of clinical complications</measure>
    <time_frame>From time of ablation to 1 month post procedure</time_frame>
    <description>Absence of clinical complications during the procedure and up to one month thereafter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural duration time</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration for pulmonary vein isolation</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic duration and irradiation (AK)</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of ablation points associated with temperature rise</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum temperature in case of temperature rise</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to ablation</measure>
    <time_frame>From time of ablation to 6 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First pass encirclement isolation rate</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconnection rate after adenosine</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dislocations</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ablation points with an oesophageal temperature rise &gt;39°C</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum temperature in case of oesophageal temperature rise</measure>
    <time_frame>At time of ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longterm procedural success rate</measure>
    <time_frame>Six months after ablation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>High power group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The experimental group will receive AF ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive AF ablation according to the standard CLOSE-protocol (35 Watt and stability criteria of 3 mm for 8 seconds)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High power CLOSE-guided PVI ablation</intervention_name>
    <description>CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)</description>
    <arm_group_label>High power group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard CLOSE-guided PVI ablation</intervention_name>
    <description>Standard AF ablation according to the CLOSE-protocol</description>
    <arm_group_label>Standard group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients referred for symptomatic paroxysmal AF and without advanced structural&#xD;
             heart disease&#xD;
&#xD;
          -  Signed Patient Informed Consent Form&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able and willing to comply with all follow-up testing and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistent atrial fibrillation (history of AF&gt;7days or history of cardioversion &gt; 48h&#xD;
             of AF)&#xD;
&#xD;
          -  Previous ablation for AF&#xD;
&#xD;
          -  LA antero-posterior diameter&gt;50 mm (parasternal long axis view , PLAX)&#xD;
&#xD;
          -  LVEF &lt;35% (ejection fraction)&#xD;
&#xD;
          -  AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          -  CABG procedure within the last three months&#xD;
&#xD;
          -  Awaiting cardiac transplantation or other cardiac surgery&#xD;
&#xD;
          -  Documented left atrial thrombus on imaging&#xD;
&#xD;
          -  Diagnosed atrial myxoma&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Acute illness or active systemic infection or sepsis&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Uncontrolled heart failure&#xD;
&#xD;
          -  Myocardial infarction within the previous two months&#xD;
&#xD;
          -  History of blood clotting or bleeding abnormalities&#xD;
&#xD;
          -  Contraindication to anticoagulation therapy (ie, heparin or warfarin)&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Enrollment in any other study evaluating another device or drug&#xD;
&#xD;
          -  Presence of intramural thrombus, tumor or other abnormality that precludes catheter&#xD;
             introduction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Wielandts JY, Kyriakopoulou M, Almorad A, Hilfiker G, Strisciuglio T, Phlips T, El Haddad M, Lycke M, Unger P, Le Polain de Waroux JB, Vandekerckhove Y, Tavernier R, Duytschaever M, Knecht S. Prospective Randomized Evaluation of High Power During CLOSE-Guided Pulmonary Vein Isolation: The POWER-AF Study. Circ Arrhythm Electrophysiol. 2021 Jan;14(1):e009112. doi: 10.1161/CIRCEP.120.009112. Epub 2020 Dec 10.</citation>
    <PMID>33300809</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Sebastien Knecht</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

